CA3138238A1 - Method for treating endometriosis-associated pain by using diaminopyrimidine compound - Google Patents
Method for treating endometriosis-associated pain by using diaminopyrimidine compound Download PDFInfo
- Publication number
- CA3138238A1 CA3138238A1 CA3138238A CA3138238A CA3138238A1 CA 3138238 A1 CA3138238 A1 CA 3138238A1 CA 3138238 A CA3138238 A CA 3138238A CA 3138238 A CA3138238 A CA 3138238A CA 3138238 A1 CA3138238 A1 CA 3138238A1
- Authority
- CA
- Canada
- Prior art keywords
- days
- lig
- compound
- nrarb
- saturated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/085209 | 2019-04-30 | ||
| CN2019085209 | 2019-04-30 | ||
| PCT/CN2020/087689 WO2020221277A1 (zh) | 2019-04-30 | 2020-04-29 | 二氨基嘧啶类化合物治疗子宫内膜异位相关的疼痛的方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3138238A1 true CA3138238A1 (en) | 2020-11-05 |
Family
ID=73028778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3138238A Pending CA3138238A1 (en) | 2019-04-30 | 2020-04-29 | Method for treating endometriosis-associated pain by using diaminopyrimidine compound |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12605381B2 (https=) |
| EP (1) | EP3960178B1 (https=) |
| JP (1) | JP7663508B2 (https=) |
| KR (1) | KR102935431B1 (https=) |
| CN (1) | CN114007620B (https=) |
| AU (1) | AU2020266947B2 (https=) |
| BR (1) | BR112021021838A8 (https=) |
| CA (1) | CA3138238A1 (https=) |
| MX (1) | MX2021013347A (https=) |
| SG (1) | SG11202111960PA (https=) |
| TW (1) | TWI737285B (https=) |
| WO (1) | WO2020221277A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7207634B2 (ja) | 2017-11-01 | 2023-01-18 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | Ｐ２ｘ３及び／又はｐ２ｘ２／３受容体アンタゴニスト、それを含む医薬組成物及びその使用 |
| US20250032476A1 (en) * | 2021-11-05 | 2025-01-30 | The Regents Of The University Of California | Alpha-2a adrenergic receptor modulators and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008104474A1 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Diaminopyrimidines |
| MA43821A (fr) * | 2016-03-14 | 2018-11-28 | Afferent Pharmaceuticals Inc | Pyrimidines et variantes de celles-ci, et leurs utilisations |
| MA44489A (fr) | 2016-03-25 | 2019-01-30 | Afferent Pharmaceuticals Inc | Pyrimidines et variants de celles-ci, et leurs utilisations |
| JP7207634B2 (ja) * | 2017-11-01 | 2023-01-18 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | Ｐ２ｘ３及び／又はｐ２ｘ２／３受容体アンタゴニスト、それを含む医薬組成物及びその使用 |
| USD956213S1 (en) | 2020-10-02 | 2022-06-28 | Phillips-Medisize A/S | Autoinjector |
-
2020
- 2020-04-29 SG SG11202111960PA patent/SG11202111960PA/en unknown
- 2020-04-29 US US17/607,475 patent/US12605381B2/en active Active
- 2020-04-29 CA CA3138238A patent/CA3138238A1/en active Pending
- 2020-04-29 KR KR1020217038622A patent/KR102935431B1/ko active Active
- 2020-04-29 EP EP20798599.5A patent/EP3960178B1/en active Active
- 2020-04-29 JP JP2021564186A patent/JP7663508B2/ja active Active
- 2020-04-29 WO PCT/CN2020/087689 patent/WO2020221277A1/zh not_active Ceased
- 2020-04-29 BR BR112021021838A patent/BR112021021838A8/pt unknown
- 2020-04-29 AU AU2020266947A patent/AU2020266947B2/en active Active
- 2020-04-29 MX MX2021013347A patent/MX2021013347A/es unknown
- 2020-04-29 CN CN202080032509.8A patent/CN114007620B/zh active Active
- 2020-04-30 TW TW109114698A patent/TWI737285B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021021838A8 (pt) | 2023-02-28 |
| JP7663508B2 (ja) | 2025-04-16 |
| BR112021021838A2 (pt) | 2022-01-04 |
| KR20220008286A (ko) | 2022-01-20 |
| CN114007620B (zh) | 2024-08-06 |
| SG11202111960PA (en) | 2021-12-30 |
| EP3960178A1 (en) | 2022-03-02 |
| JP2022531570A (ja) | 2022-07-07 |
| US20220249478A1 (en) | 2022-08-11 |
| MX2021013347A (es) | 2022-01-24 |
| TW202106303A (zh) | 2021-02-16 |
| KR102935431B1 (ko) | 2026-03-05 |
| CN114007620A (zh) | 2022-02-01 |
| WO2020221277A1 (zh) | 2020-11-05 |
| EP3960178B1 (en) | 2026-03-18 |
| US12605381B2 (en) | 2026-04-21 |
| TWI737285B (zh) | 2021-08-21 |
| AU2020266947A1 (en) | 2021-12-16 |
| EP3960178A4 (en) | 2023-01-25 |
| AU2020266947B2 (en) | 2025-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3692040B1 (en) | Chemical compounds | |
| JP6926189B2 (ja) | エストロゲン受容体調節薬 | |
| CA2939219C (en) | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease | |
| CA3099151A1 (en) | Substituted heterocyclic inhibitors of ptpn11 | |
| AU2017274199A1 (en) | Heterocyclic inhibitors of PTPN11 | |
| CA2863517C (en) | Substituted pyrimidine compounds and their use as syk inhibitors | |
| BR112012021889B1 (pt) | Compostos de amidas heterocíclicas e composição que as compreende para a prevenção ou o tratamento de doenças oculares | |
| KR20160079082A (ko) | 오토탁신 억제제 화합물 | |
| AU2020230574A1 (en) | Method for treating fatty liver disease and/or steatohepatitis | |
| CA2939012C (en) | Pyrrole-substituted indolone derivative, preparation method therefor, composition comprising the same and use thereof | |
| CA3138238A1 (en) | Method for treating endometriosis-associated pain by using diaminopyrimidine compound | |
| TW202440553A (zh) | 作為at2r拮抗劑的雜環化合物 | |
| BR112021003949A2 (pt) | derivado de anel fundido usado como inibidor de fgfr4 | |
| EP3746444A1 (en) | Cycloalkyl substituted pyrazolopyrimidines having activity against rsv | |
| CZ289533B6 (cs) | Pouľití dihydropyridinových derivátů s anelovanými uhlíkovými nebo heterocyklickými kruhy pro výrobu farmaceutických prostředků k ochraně mozkové tkáně | |
| TW202515864A (zh) | 一種at2r拮抗劑及其用途 | |
| CN118234716A (zh) | 艾地苯醌衍生物及其在治疗植物中的用途 | |
| EP3960179B1 (en) | Method for treating cough by using diaminopyrimidine compound | |
| CA3138780C (en) | Method for treating cough by using diaminopyrimidine compound | |
| IL299985A (en) | A method for treating graft-versus-Maschen disease caused by hematopoietic stem cell transplantation | |
| HK40062123A (en) | Method for treating endometriosis-associated pain by using diaminopyrimidine compound | |
| HK40063619A (en) | Method for treating endometriosis-associated pain by using diaminopyrimidine compound | |
| TW202502346A (zh) | 作為at2r拮抗劑的雜環化合物及其用途 | |
| KR20250170567A (ko) | 치환된 아세틸렌 화합물 유도체 및 이의 약제학적 용도 | |
| HK40063619B (zh) | 二氨基嘧啶类化合物治疗子宫内膜异位相关的疼痛的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220718 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240802 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241202 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250203 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250319 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250319 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250319 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260325 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260326 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260328 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260330 |